Difference between revisions of "Programmed death-ligand 1"
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
It is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref> | It is also known as '''CD274'''.<ref name=omim>{{OMIM|605402}}</ref> | ||
== | ==Prognosis== | ||
*Good prognosis - in high-grade [[ovarian serous carcinoma]], associated with [[tumour-infiltrating lymphocytes]].<ref name=pmid26972336>{{Cite journal | last1 = Webb | first1 = JR. | last2 = Milne | first2 = K. | last3 = Kroeger | first3 = DR. | last4 = Nelson | first4 = BH. | title = PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. | journal = Gynecol Oncol | volume = 141 | issue = 2 | pages = 293-302 | month = May | year = 2016 | doi = 10.1016/j.ygyno.2016.03.008 | PMID = 26972336 }}</ref> | |||
==Application of PD-L1 antibodies== | |||
PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue = | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref> | PD-L1 antibodies are being used to treat:<ref name=pmid26895815>{{Cite journal | last1 = Gandini | first1 = S. | last2 = Massi | first2 = D. | last3 = Mandalà | first3 = M. | title = PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. | journal = Crit Rev Oncol Hematol | volume = 100 | issue = | pages = 88-98 | month = Apr | year = 2016 | doi = 10.1016/j.critrevonc.2016.02.001 | PMID = 26895815 }}</ref> | ||
*[[Malignant melanoma]]. | *[[Malignant melanoma]]. | ||
Revision as of 03:39, 4 May 2016
Programmed death-ligand 1, commonly abbreviated PD-L1, is protein with an important role in immune system regulation, and thus cancer aggressiveness.
It is also known as CD274.[1]
Prognosis
- Good prognosis - in high-grade ovarian serous carcinoma, associated with tumour-infiltrating lymphocytes.[2]
Application of PD-L1 antibodies
PD-L1 antibodies are being used to treat:[3]
See also
References
- ↑ Online 'Mendelian Inheritance in Man' (OMIM) 605402
- ↑ Webb, JR.; Milne, K.; Kroeger, DR.; Nelson, BH. (May 2016). "PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.". Gynecol Oncol 141 (2): 293-302. doi:10.1016/j.ygyno.2016.03.008. PMID 26972336.
- ↑ Gandini, S.; Massi, D.; Mandalà, M. (Apr 2016). "PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.". Crit Rev Oncol Hematol 100: 88-98. doi:10.1016/j.critrevonc.2016.02.001. PMID 26895815.